Table 1.
Combination Index (CI) to assess the degree of drug combination using the CompuSyn software
| Cell Lines | Treatment | Parameters | CI Value | DRUI Value | ||
|---|---|---|---|---|---|---|
| Dm | m | r | ||||
| 22Rν1 | Fisetin | 27.0305 | −0.7615±0.17257 | −0.9753 | 8.34449 | |
| Cabazitaxel | 7.71559 | −2.1193±0.18013 | −0.9964 | 2.96809 | ||
| Combination (4000:1) | 0.45676 | |||||
| PC-3 | Fisetin | 0.24692 | −0.353±0.01560 | −0.9990 | 1.35079 | |
| Cabazitaxel | 0.02675 | −0.1611 | −1.0000 | 158.195 | ||
| Combination (4000:1) | 0.74663 | |||||
| C4-2 | Fisetin | 3.62164 | −0.9983±0.21078 | −0.9784 | 1.39825 | |
| Cabazitaxel | 0.39547 | −0.2726±0.10660 | −0.9313 | 141.146 | ||
| Combination (4000:1) | 0.72226 | |||||
Fisetin (20 μM), cabazitaxel (5nM) and the combination (Fisetin 20 μM and cabazitaxel 5nM) synergistically inhibit cell viability in 22Rν1, PC-3M and C4-2 cell lines. Slope (m), correlation coefficients (r), and median-effect dosages (Dm) from median-effect plots, combination indexes (CI) and dose-reduction indexes (DRI) for fisetin alone, cabazitaxel alone, and fisetin and cabazitaxel combination treatment.